A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Enrollment for a randomized phase 2 trial designed to compare a triplet regimen and doublet regimen for certain patients with leukemia has been discontinued due to low likelihood of benefit.The ...

Triplet Better Than Doublet in mCSPC? Not Always, Say Experts Neil Osterweil March 03, 2023 0 ...

Cite this: Which Metastatic Hormone-Sensitive Prostate Cancer Patients Are the Best Candidates for Doublet and Triplet Therapies? - Medscape - Oct 24, 2023.

The median time to CR/CRi was 21 days and 25 days for the triplet and doublet arms, respectively. By the end of cycle 1, 100% of patients in the triplet arm achieved CR/CRi vs 60% of those in the ...

Also at week 26 for the secondary end points, increases of 55 and 56.4 meters were seen, respectively, for the triplet and doublet regimens, “while the geometric mean for the ratio of baseline ...

What I would say about the results from STELLAR-002 is that the side effects in the doublet — zanzalintinib plus Opdivo — versus the triplet — zanzalintinib plus Opdivo and Opdualag — were fairly ...

Median foll0w-up was 20.2 months. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 73% of patients receiving the triplet combination compared with 41% receiving the doublet combination.